Pam Mangat

23PUBLICATIONS
79CO-AUTHORS
Molecular targetsMedical bacteriologyPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Jul 15, 2026
Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

|Apr 30, 2026
Pertuzumab and Trastuzumab in Patients With ERBB2/3-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study.

|Apr 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.

|Apr 22, 2026
Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

|Jan 15, 2026
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Daniel R Carrizosa, Michael Rothe, Pam K Mangat

|Oct 16, 2025
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Tareq Al Baghdadi, Michael Rothe, Pam K Mangat

Pageof 4

Frequent Collaborators

22 joint publications

Elizabeth Garrett-Mayer

20 joint publications

Susan Halabi

20 joint publications

Gina N Grantham

20 joint publications

Richard L Schilsky